STARPHARMA HOLD/S (OTCMKTS:SPHRY) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Valuation & Earnings

This table compares STARPHARMA HOLD/S and Cleveland BioLabs’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
STARPHARMA HOLD/S $3.79 million 74.79 -$7.97 million N/A N/A
Cleveland BioLabs $1.95 million 8.05 -$9.70 million N/A N/A

STARPHARMA HOLD/S has higher revenue and earnings than Cleveland BioLabs.

Insider & Institutional Ownership

4.6% of Cleveland BioLabs shares are held by institutional investors. 2.0% of Cleveland BioLabs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


This table compares STARPHARMA HOLD/S and Cleveland BioLabs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs -245.29% -75.80% -56.63%

Analyst Recommendations

This is a summary of current ratings and recommmendations for STARPHARMA HOLD/S and Cleveland BioLabs, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STARPHARMA HOLD/S 0 0 1 0 3.00
Cleveland BioLabs 0 0 0 0 N/A

Risk and Volatility

STARPHARMA HOLD/S has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.


STARPHARMA HOLD/S beats Cleveland BioLabs on 8 of the 10 factors compared between the two stocks.


Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive News & Ratings for STARPHARMA HOLD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STARPHARMA HOLD/S and related companies with's FREE daily email newsletter.